Prevalence and thrombotic risk of platelet factor 4–dependent platelet-activating antibodies
Journal of Thrombosis and Haemostasis · 2026-11 · 24 (11) · 4076-4084
DOI: 10.1016/j.jtha.2026.07.026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026-11. Verfasst von Leonard Scheuer und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institut für Transfusionsmedizin, Universitätsmedizin Greifswald, Greifswald, Germany. Hauptthemen laut MEDLINE: Platelet Factor 4, Thrombosis, Platelet Activation, Thrombocytopenia. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: American Society of Hematology Inc, European Medicines Agency, Else Kröner-Fresenius-Stiftung.
Abstract (Originalsprache)
BACKGROUND: Platelet-activating anti-platelet factor 4 (PF4) antibodies cause heparin-induced thrombocytopenia (HIT) and vaccine-induced immune thrombocytopenia and thrombosis. Vaccine-induced immune thrombocytopenia and thrombosis also occurs independent of vaccination. Prevalence and clinical relevance of heparin-dependent HIT antibodies are well described, but information on heparin-independent anti-PF4 antibodies in larger populations remains limited. OBJECTIVES: To determine the prevalence of PF4-dependent and heparin-dependent platelet-activating antibodies in patients referred for evaluation of suspected HIT or other anti-PF4 disorders and to assess their association with thrombotic complications and thrombocytopenia. METHODS: Over 10 months, we conducted a cohort study assessing consecutive patient sera referred to the Greifswald laboratory for anti-PF4 antibody testing, with an in-house anti-PF4/heparin immunoglobulin G enzyme immunoassay (EIA) optical density (OD) ≥1.0, by heparin- and PF4-dependent functional assays (heparin-induced platelet activation [HIPA] and PF4-induced platelet activation [PIPA]) and obtained clinical data with focus on thrombosis. RESULTS: In 474 study subjects (EIA OD ≥1.0), platelet-activating PF4-dependent antibodies were detected in 227 patients (47.9%) by functional assays, including 22 patients (6.7%) with isolated PF4-dependent platelet activation (PIPA+/HIPA-). Clinical data on thrombosis were available for 329 of 474 patients (69.4%). In this subgroup, prevalence of thrombosis increased numerically with higher EIA OD values (OD range 1.0 to
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institut für Transfusionsmedizin, Universitätsmedizin Greifswald, Greifswald, Germany.
- Institut für Community Medicine, Universitätsmedizin Greifswald, Greifswald, Germany.
- Institut für Transfusionsmedizin, Universitätsmedizin Greifswald, Greifswald, Germany. Electronic address: linda.schoenborn@med.uni-greifswald.de.
Förderung
- American Society of Hematology Inc
- European Medicines Agency
- Else Kröner-Fresenius-Stiftung
- German Research Foundation
Zitieren
APA
Scheuer, L., Wesche, J., Weitmann, K., Thiele, T., Greinacher, A., & Schönborn, L. (2026). Prevalence and thrombotic risk of platelet factor 4–dependent platelet-activating antibodies. Journal of Thrombosis and Haemostasis, 24(11), 4076-4084. https://doi.org/10.1016/j.jtha.2026.07.026
Vancouver
Scheuer L, Wesche J, Weitmann K, Thiele T, Greinacher A, Schönborn L. Prevalence and thrombotic risk of platelet factor 4–dependent platelet-activating antibodies. Journal of Thrombosis and Haemostasis. 2026;24(11):4076-4084. doi:10.1016/j.jtha.2026.07.026
BibTeX
@article{Scheuer2026,
author = {Scheuer, Leonard and Wesche, Jan and Weitmann, Kerstin and Thiele, Thomas and Greinacher, Andreas and Schönborn, Linda},
title = {Prevalence and thrombotic risk of platelet factor 4–dependent platelet-activating antibodies},
journal = {Journal of Thrombosis and Haemostasis},
year = {2026},
volume = {24},
number = {11},
pages = {4076--4084},
doi = {10.1016/j.jtha.2026.07.026}
}
EUVIMED